Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Abstract Background Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. Methods This prospective, multicentre, rAnibizumab bioSimilar...

Full description

Bibliographic Details
Main Authors: Shashikant Sharma, Vishali Gupta, Aniruddha Maiti, Sribhargava Natesh, Sandeep Saxena, Vivek Dave, Vimal Parmar, Raju Sampangi, Hemanth Murthy, Sandhya Dharwadkar, Naresh Kumar Yadav, Shrinivas Joshi, Rahul Mayor, Dhanashree Ratra, Soumyava Basu, Neha Goel, Alok Chaturvedi, Ronak Patel, Vinu Jose
Format: Article
Language:English
Published: BMC 2021-03-01
Series:International Journal of Retina and Vitreous
Subjects:
Razumab
Biosimilar ranibizumab
Neovascular
Wet age-related macular degeneration
AMD
Safety
Online Access:https://doi.org/10.1186/s40942-021-00293-w

Internet

https://doi.org/10.1186/s40942-021-00293-w

Similar Items